American Marconi Wireless News - IGC Pharma Announces Preclinical Data Demonstrating TGR-63’s Dual Action on Alzheimer’s Pathology

"These results underscore the potential of TGR-63 as a differentiated, dual-acting candidate that targets both beta-amyloid and tau, two central drivers of Alzheimer's pathology," said Ram Mukunda, CEO of IGC Pharma. "By broadening our portfolio with this important addition, we are strengthening IGC's capabilities in developing safer and more effective therapies that go beyond the limitations of current treatments. We are continuing to advance the preclinical evaluation of TGR-63 as we work toward building a pipeline of truly disease-modifying solutions for Alzheimer's."

In in vitro assays, TGR-63 was shown to suppress tau fibril formation at micromolar concentrations, suggesting its ability to interfere with the development of neurofibrillary tangles strongly associated with neuronal dysfunction and cognitive decline. This activity complements prior findings that TGR-63 effectively disrupts Aβ plaque aggregation.

Additionally, serum stability studies confirmed that TGR-63 retains its structural integrity under physiological conditions. The compound remained stable when incubated in phosphate-buffered saline (PBS) and mouse blood serum at 37 °C for several hours.

Complementary MALDI mass spectrometry further detected TGR-63 in serum samples at both 1- and 24-hours post-administration, supporting its pharmacological resilience and systemic delivery potential.

These encouraging findings validate TGR-63's dual mechanism of action, which is protected under IGC Pharma's patent portfolio. Building on this foundation, the Company is well-positioned to advance TGR-63 through continued preclinical development with the goal of establishing a novel, disease-modifying approach to Alzheimer's that is distinct from current single-target therapies.

About IGC Pharma (dba IGC):

IGC Pharma (NYSE American:IGC) is a clinical-stage biotechnology company leveraging AI to develop innovative treatments for Alzheimer's and metabolic disorders. Our lead asset, IGC-AD1, is a cannabinoid-based therapy currently in a Phase 2 trial (CALMA) for agitation in Alzheimer's dementia. Our pipeline includes TGR-63, targeting amyloid plaques, and early-stage programs focused on neurodegeneration, tau proteins, and metabolic dysfunctions. We integrate AI to accelerate drug discovery, optimize clinical trials, and enhance patient targeting. With 30 patent filings and a commitment to innovation, IGC Pharma is advancing breakthrough therapies.

Forward-Looking Statements:

This press release contains forward-looking statements. These forward-looking statements are based largely on IGC Pharma's expectations and are subject to several risks and uncertainties, certain of which are beyond IGC Pharma's control. Actual results could differ materially from these forward-looking statements as a result of, among other factors, the Company's failure or inability to commercialize one or more of the Company's products or technologies, including the products or formulations described in this release, or failure to obtain regulatory approval for the products or formulations, where required, or government regulations affecting AI or the AI algorithms not working as intended or producing accurate predictions; general economic conditions that are less favorable than expected; the FDA's general position regarding cannabis- and hemp-based products; and other factors, many of which are discussed in IGC Pharma's U.S. Securities and Exchange Commission ("SEC") filings. IGC incorporates by reference its Annual Report on Form 10-K filed with the SEC on June 27, 2025, as if fully incorporated and restated herein. Considering these risks and uncertainties, there can be no assurance that the forward-looking information contained in this release will occur. IGC Pharma, Inc. assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.

Contact Information

Rosalyn Christian / John Nesbett
IMS Investor Relations
[email protected]
(203) 972-9200

SOURCE: IGC Pharma, Inc.

View the original press release on ACCESS Newswire

L.Mason--AMWN